Condition 1: Hemodialysis. Condition 2: Iron deficiency anaemia. Extracorporeal dialysis Iron deficiency anaemia, unspecified
Conditions
Interventions
Intervention 1: Iron sucrose (Venofor st . Gallen/Switzerland) 100 mg diluted in 100 ml of Normal Saline, postdialysis, twice a week , during the first 5 weeks of the study in case group. Interventio
Treatment - Drugs
Iron sucrose (Venofor st . Gallen/Switzerland) 100 mg diluted in 100 ml of Normal Saline, postdialysis, twice a week , during the first 5 weeks of the study in case group.
Ascorbic acid 300 mg Intravenous postdialysis, twice a week for 5 consecutive weeks in control group.
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1) Ferritin level = 500ng/ml and TSAT= 25%; 2) Hemodialysis therapy for = 3 months; 3) Duration of recombinant human Erythropoietin (rHYEPO) treatment = 6 months at lest 6000 u/week; 4)Hemoglobin level < 11 gr/dl and Stable hemoglobin levels for four consecutive weeks; 5)The Hemodialysis patients= 18 years and<70 years. Exclusion criteria: 1) Blood transfusion during 3 months ago; 2) Blood loss during 3 months ago; 3) Acute infection; 4) Chronic inflammatory disease; 5) Active liver disease; 6) Hemoglobinopathy such as sickle cell disease; 7) Adminstration of intravenous Iron during 3 months ago.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin. Timepoint: Before the drug adminstration and at the 12 weeks after the start of drug adminstration. Method of measurement: computerized coulter counter(Abbot Machine made in USA). | — |
Secondary
| Measure | Time frame |
|---|---|
| Sreum Ferritin. Timepoint: Before the drug adminstration and at the 12 weeks after the start of drug adminstration. Method of measurement: In ng/ml and will measure by LIAZON kit(made in Italy).;Serum Iron. Timepoint: Before the drug adminstration and at the 12 weeks after the start of drug adminstration. Method of measurement: In ng/ml and will measure by Pars Azmoon kit (made in Iran) and Hitachi analyzer (Model 911, made in Japan).;Total Iron Binding Capacity(TIBC). Timepoint: Before the drug adminstration and at the 12 weeks after the start of drug adminstration. Method of measurement: In mg/dl and will measure by Pars Azmoon kit(made in Iran) and Hitachi analyzer (Model 911, made in Japan).;Transferrin Saturation(TSAT). Timepoint: Before the drug adminstration and at the 12 weeks after the start of drug adminstration. Method of measurement: In Percent and will calculate by dividing serum Iron by TIBC x 100. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactOmid Sedighi
Mazandaran University of Medical Sciences
Outcome results
None listed